Shares of C.R. Bard (NYSE:BCR) saw an erosion of -0.11 points in recent session. During the trading, the value of each share was $227.67, dropping -0.05%. The shares saw high fund-flow as the composite value of all the upticks was $8.19 million and the total value of all the downticks was a mere $6.15 million. The net money flow was seen at $2.05 million and the up/down ratio was measured at 1.33. On a weekly basis the shares of the shares have recorded a change of 1.17%.
The stock has recorded a 20-day Moving Average of 2.44% and the 50-Day Moving Average is 5.29%. The company shares have rallied 31.69% in the past 52 Weeks. On June 20, 2016 The shares registered one year high of $228.69 and one year low was seen on July 7, 2015 at $169.09. The 50-day moving average is $220.69 and the 200 day moving average is recorded at $199.66. S&P 500 has rallied 1.93% during the last 52-weeks.
C.R. Bard (NYSE:BCR): During Tuesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $228.64 and $226.76 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $229.61. The buying momentum continued till the end and the stock did not give up its gains. It closed at $228.22, notching a gain of 0.19% for the day. The total traded volume was 323,861 . The stock had closed at $227.78 on the previous day.
Currently the company Insiders own 0.97% of C.R. Bard shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -5.91% . Institutional Investors own 93.07% of C.R. Bard shares. During last six month period, the net percent change held by insiders has seen a change of -14.77%. On the companys insider trading activities,The officer (Senior Vice President and CFO) of Bard C R Inc /Nj/, Holland Christopher S sold 3,970 shares at $219.88 on May 27, 2016. The Insider selling transaction had a total value worth of $872,924. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
C. R. Bard, Inc. (Bard) and its subsidiaries are engaged in the design, manufacture, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. . The Company reports its sales in four major product group categories: vascular, urology, oncology and surgical specialty. The Company also has a product group of other products. The Companys vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and heart arrhythmias. Its urology products include basic urology drainage products, fecal and urinary continence products, urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and other soft tissue repairs, in addition to hemostats and surgical sealants.